Patent Information:
For Information, Contact:
Rachel Hemsley
Senior Business Manager
UCL Business PLC
020 7679 9000
r.hemsley@uclb.com
Keywords:
Ophthalmology & Optometry

Antibody Tablet for Occular Therapeutics Delivery

Case ID:
88-078
Web Published:
01/03/2011
Description:

Available For: Exclusive licensing

<h2>Summary</h2>

A novel solid formulation for the delivery of antibodies and protein therapeutics into the eye. This has several advantages over current methodologies which involve painful intraocular injections.

<h2>The Technology and its Advantages</h2>

Antibody therapies are being used to treat highly prevalent eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and other vascular conditions. Therapies such as the blockbuster Lucentis are currently delivered by repeat intraocular injections. Such injections are painful, inconvenient and disliked by patients. Rapid clearance of the antibodies requires repeat injections and results in high dose dumping. Prolonged release can be achieved through an implantable tablet.

We have developed a solid formulation methodology for antibodies and protein therapeutics delivery into the eye. This tablet provides prolonged release of the API and reduces the need for repeat injections.

<h2>Market Opportunity</h2>

Ocular anti-neovascularisation preparations, used for the treatment of wet AMD, accounted for $1.8bn in sales in 2008. The segment captured 13.4% of the ophthalmic pharmaceutical market, while showing a year on year growth of 29.8%. Lucentis dominated the field with $1.6bn of sales (Business Insights, 2009).

In the pharmaceutical market, monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate (CAGR) of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. Additionally, MAbs are expected to provide the biggest portion of absolute sales growth (Datamonitor 2010). Novel drug delivery methods are increasingly being sought for such therapies.

<h2>Intellectual Property Status</h2>

Patent pending (WO2012046009)

<h2>Further Information</h2>

Please contact Rachel Hemsley, Senior Business Manager  | T:+44 (0)20 7679 9000 |E: r.hemsley@uclb.com 

The technology referred to herein is experimental in nature and UCL Business PLC makes no representations and gives no warranties of any kind, either express or implied, in relation to the technology and, in particular but without limiting the foregoing, UCL Business PLC gives no express or implied warranties of merchantability, satisfactory quality or fitness for a particular purpose.

© 2017. All Rights Reserved. Powered by Inteum